Alimentiv

Alimentiv is a premier, privately-held gastrointestinal CRO with a dominant position in inflammatory bowel disease (IBD) trials, having supported over 70% of IBD compounds in development. Its business model is service-based, offering a full suite of clinical trial services enhanced by proprietary central reading technologies and endpoints like the UC-100 Score and Robarts Histopathology Index. With a global network of over 5,000 sites and a strong publication record, the company is a revenue-generating partner for biopharma clients seeking specialized GI trial execution.

Integrated suite of GI-specific clinical trial service platforms, including: Central Imaging Management System (CIMS) for endoscopy; AI-Powered Endoscopy solutions; proprietary histopathology indices (e.g., Robarts Histopathology Index); centralized reading for non-invasive imaging (IUS, MRE); and end-to-end laboratory & biomarker services via AcelaBio.

Alimentiv competes primarily with the GI/therapeutic specialty units of large, global CROs (e.g., IQVIA, Parexel, ICON) and smaller boutique GI CROs. Its key competitive advantage is its decades-deep, exclusive focus on GI, proprietary endpoint methodologies, and fully integrated service model from strategy to central lab, which generalists cannot easily replicate.